February 2019, Volume 5, Issue 3

February 2019

Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.

Table of Contents

February 2019 Issue

An ASH Annual Meeting Post-Vivum

Friday, February 1st, 2019
“So, what did you learn from ASH?” asked my advisor a couple of weeks after I returned from my first American Society of Hematology...

Cinder, a New Dating App From ASH!*

Friday, February 1st, 2019
In preparation for Valentine’s Day, ASH Clinical News has been trolling for ways to promote that most elusive of emotions – love – while...

February 2019 Issue

ASH Directions

An Advocacy Win for Sickle Cell Disease

Friday, February 1st, 2019
An Advocacy Win for Sickle Cell Disease As part of a multifaceted initiative to address the burden of sickle cell disease (SCD) in the U.S....
The Society Pages

Remembering Evan Sadler and Charles Dobbs, and more

Friday, February 1st, 2019
Remembering Evan Sadler (1951 – 2018) Evan Sadler III, MD, PhD, the Lang Professor of Medicine and Chief of Hematology at Washington University in St....

February 2019 Issue

Finding Homes for Orphans

Friday, February 1st, 2019
The unique challenges of researching, managing, and developing orphan drugs for rare diseases Rare diseases are having a moment, and not just in the field...

Pulling Back the Curtain: Peter Marks, MD, PhD

Friday, February 1st, 2019
In this edition, Peter Marks, MD, PhD, talks about career-hopping, serving the public, and landing his dream job. Dr. Marks is director of the...

February 2019 Issue

You Make the Call

Best options for an older patient with Ph+ B-cell ALL

Friday, February 1st, 2019
This month, Wendy Stock, MD, discusses best options for an older patient with Philadelphia chromosome (Ph)–positive B-cell acute lymphocytic leukemia (ALL). And don't forget to...

February 2019 Issue

FDA Approves Calaspargase Pegol-mknl for Acute Lymphocytic Leukemia

Friday, February 1st, 2019
The FDA approved calaspargase pegol-mknl, an asparagine-specific enzyme, for the treatment of pediatric and young adult patients (ages 1 month to 21 years) with...

Cigna and Express Scripts Seal $54 Billion Merger

Friday, February 1st, 2019
Health insurer Cigna completed its $54 billion acquisition of Express Scripts, which manages the prescription plans of more than 80 million Americans. The announcement...

FDA Expands Romiplostim Indication to Pediatric ITP

Friday, February 1st, 2019
The U.S. Food and Drug Administration (FDA) approved romiplostim for the treatment of immune thrombocytopenia (ITP) in children younger than age 1 whose disease...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

Friday, February 1st, 2019
According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...

Apixaban AVERTs Cancer-Associated Venous Thromboembolism

Friday, February 1st, 2019
In the randomized, placebo-controlled AVERT trial, investigators assessed the safety and efficacy of apixaban thromboprophylaxis in patients with cancer considered to be at intermediate-...
WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With ALL

Friday, February 1st, 2019
Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...
WIB_icon

Study Identifies Genetic Markers That Predict Radiation-Induced Breast Cancer After Hodgkin Lymphoma

Friday, February 1st, 2019
The risk of developing breast cancer is high in women with Hodgkin lymphoma (HL) who have undergone chest radiotherapy (RT), but the role of...

NCI Trims Operating Expenses for 2019

Friday, February 1st, 2019
Despite receiving a larger budget for fiscal year 2019 – a $179-million increase over the previous year – the National Cancer Institute (NCI) plans...
WIB_icon

Azacitidine Maintenance Improves Disease-Free Survival in Older Patients with Newly Diagnosed AML

Friday, February 1st, 2019
Older patients with acute myeloid leukemia (AML) in complete remission (CR) who received maintenance therapy with subcutaneous azacitidine had longer disease-free survival (DFS), compared...

February 2019 Issue

Transplant or No Transplant for Older, Fit Patients With MDS?

Friday, February 1st, 2019
Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with advanced myelodysplastic syndromes (MDS), compared with OS in patients...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

Friday, February 1st, 2019
One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab responded to treatment with melflufen, according to interim data...

Mixed Results for Immunotherapy Approaches in Myelodysplastic Syndromes

Friday, February 1st, 2019
Findings from trials evaluating new treatment strategies for patients with myelodysplastic syndromes (MDS) produced mixed results: Combining an immune checkpoint inhibitor with azacitidine was...

Predicting Response to Alvocidib in Patients With Relapsed/Refractory AML

Friday, February 1st, 2019
The CDK9 inhibitor alvocidib induced a high rate of responses in patients with relapsed or refractory acute myeloid leukemia (AML) who had MCL1-dependent disease,...

Age, Blood Type, and Rituximab Use Associated With Relapse Risk in TTP

Friday, February 1st, 2019
For patients with thrombotic thrombocytopenic purpura (TTP), treatment with rituximab prevented relapse in the first year after administration, but the protective effect waned over...

Evaluating Imetelstat for Patients With Relapsed/Refractory Myelofibrosis

Friday, February 1st, 2019
In a phase II trial presented at the 2018 ASH Annual Meeting conducted in patients with higher-risk myelofibrosis (MF) who had relapsed following or...

Predicting Thrombosis and Mortality in Patients With Sickle Cell Disease

Friday, February 1st, 2019
Two studies presented at the 2018 ASH Annual Meeting characterized the risk for complications, and offered models for predicting these risks, in patients with...

SHARE